

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/833,675	04/13/2001	Thomas Weimer	06478.1454-00	2127
22852 75	590 03/26/2003			
	HENDERSON, FAR	EXAMINER		
LLP 1300 I STREET, NW WASHINGTON DG 20005			LY, CHEYNE D	
WASHINGTON, DC 20005		ſ	ART UNIT	PAPER NUMBER
			1631	4
		1	DATE MAILED: 03/26/2003	t

Please find below and/or attached an Office communication concerning this application or proceeding.

,	Application No.	Applicant(s)					
Office Action Summany	09/833,675	WEIMER, THOMAS					
Office Action Summary	Examiner	Art Unit					
	Cheyne D Ly	1631					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status							
1) Responsive to communication(s) filed on							
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ Thi	s action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims							
4)⊠ Claim(s) <u>10-34</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) 10-34 are subject to restriction and/or	election requirement						
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)⊠ All b) Some * c) None of:							
1. Certified copies of the priority documents	have been received.						
2. Certified copies of the priority documents	have been received in Application	on No					
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received.							
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)							
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)							
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)  5) Notice of Informal Patent Application (PTO-152)  6) Other:							

Art Unit: 1631

### **DETAILED ACTION**

Page 2

1. The art unit designated for this application has changed. Applicants(s) are hereby informed that future correspondence should be directed to Art Unit 1631.

#### Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 10-25, drawn to a process for identifying one or more heterologous oligonucleotide sequences for use in amplifying a target nucleic acid sequence, classified in class 435, subclass 91.2. If this Group is elected, then the below summarized sequence election is required. If this Group is elected, then the below summarized specie election is also required.
  - II. Claims 26-34, drawn to a reagent set for use in amplifying a nucleic acid sequence by polymerase chain reaction, classified in class 536, subclass 24.3. If this Group is elected, then the below summarized sequence election is required.

### **Sequence Election Requirement Applicable to All Groups:**

3. In addition, each Group detailed above reads on patentably distinct sequences. Each sequence is patentably distinct because they are unrelated sequences, and a further restriction is applied to each Group. For an elected Group draw to amino acid/polypeptide sequence, the Applicants must further elect a single amino acid/polypeptide sequence. For an elected Group drawn to nucleotide sequences, the Applicants must elect a single nucleic sequence (See MPEP § 803.04). It is noted that the multiple of sequence submissions for examination has resulted in an undue search burden if more than one nucleic acid sequence is elected, thus making the previous waiver for up to 10 elected nucleic sequences effectively impossible to reasonably implement.

Application/Control Number: 09/833,675 Page 3

Art Unit: 1631

Applicants may also elect an unspecified sequence rather than a specifically disclosed sequence.

This election corresponds to invention embodiments as instantly claimed which lack specific

sequence limitation(s).

MPEP § 803.04 states:

4. Nucleotides sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions with the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq. Examination will be restricted to only the elected sequence. It is additionally noted

that this sequence election requirement is a restriction and not a specie election requirement.

## SPECIE ELECTION REQUIREMENT FOR GROUP I:

- 5. This application contains claims directed to the following patentably distinct species of the claimed invention:
- 6. Species of amplification methods are cited in claim 24, which are generally separately analyzed and published, and thus document the undue search burden if searched together. Thus, applicant is required to select an unspecified method or a type of amplification method from those listed in claim 24.
- 7. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 10-23 and 25 are generic to the above species of amplification methods.

Art Unit: 1631

Page 4

- 8. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.
- 9. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).
- 10. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 11. Inventions of Groups I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant application, the process for identifying one or more heterologous oligonucleotide sequences for use in amplifying a target nucleic acid sequence was used to identify a reagent set which includes at least one of the oligonucleotide primers selected from SEQ ID NOs. listed in claim 27, alternatively the said process may be used to identify oligonucleotide primers not listed

Art Unit: 1631

in this instant application. As stated in the Sequence Election Requirement above, each sequence

is patentably distinct because they are unrelated sequences. Therefore, the lack of overlapping

searches documents the undue search burden if they were search together.

12. Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art as shown by their different classification, restriction for examination

purposes as indicated is proper.

13. Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

14. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

15. Papers related to this application may be submitted to Technical Center 1600 by facsimile

transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located

in Crystal Mall 1. The faxing of such papers must conform with the notices published in the

Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 193), and 1157

OG 94 (December 28, 1993) (see 37 CFR § 1.6(d)). The CM1 Fax Center number is either (703)

308-4242 or (703) 305-3014.

Page 5

Art Unit: 1631

16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to C. Dune Ly, whose telephone number is (703) 308-3880. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

- 17. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, Ph.D., can be reached on (703) 308-4028.
- 18. Any inquiry of a general nature or relating to the status of this application should be directed to Legal Instruments Examiner, Tina Plunkett, whose telephone number is (703) 305-3524 or to the Technical Center receptionist whose telephone number is (703) 308-0196.

C. Dune Ly 3/24/03

ARDIN H. MARSCHEL PRIMARY EXAMINER Page 6